alexa FLT3L-Primed In Situ Vaccine For Patients With Low-grade Lymphoma: Tumor Regression At Untreated Sites (NCT01976585)
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd International Conference and Exhibition on Clinical & Cellular Immunology
September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Joshua Brody, Seunghee Kim-Schulze, Nina Bhardwaj and Miriam Merad
Accepted Abstracts: J Clin Cell Immunol
DOI: 10.4172/2155-9899.S1.019
Abstract
Objectives: Though low-grade lymphoma is generally incurable, T-cell based therapy such as allogeneic transplant can induce prolonged remissions, possibly cures, even for chemo-resistant disease. If anti-tumor T cell immunity could be mobilized without the morbidity of transplant, it could change the paradigm of lymphoma therapy. Previously, we completed three trials of an 'in situ vaccine' combining low-dose XRT with intratumoral administration of a TLR agonist demonstrating partial and complete remissions of patients? non-irradiated sites of disease, lasting as long as 4+ years. One obstacle to the induction of potent anti-tumor immunity with the in situ vaccine approach is the paucity of professional antigen presenting cells, e.g. dendritic cells (DC) at the tumor site. Methods: To address this problem, we have adopted the approach by adding a priming step of intratumoral administration of the predominant DC differentiation factor - Flt3L. The aim of the adopted approach is to use: ? intratumoral Flt3L administration to recruit DC to the tumor, ? low-dose XRT to induce immunogenic cell death and release tumor-associated antigens, and ? intratumoral poly-ICLC administration to activate tumor antigen-loaded DC, inducing anti-tumor T cells and anti-tumor immunity. Results: Preliminary immune correlative data for the first two patients receiving the in situ vaccine demonstrate a significant (up to 200-fold) increase in the proportion of intratumoral DC subsets (BDCA-1 and BDCA-3) at the treated tumor site. We also observe a marked increase in the intratumoral proportion of CD80 (high) PD-L1 (low) activated DCs after XRT and poly- ICLC administration. This latter finding is in contrast to the activation status of DC in the peripheral blood. Conclusions: Flt3L-primed in situ vaccination demonstrates immunologic and clinical proof-of-principle and warrants continued investigation. We will present additional immunologic and clinical results as well as ongoing studies to quantify anti-tumor T cells and to determine potential tumor-associated antigens
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords